The risk of disease highlights the necessity of point‐of‐care testing. Here, a ternary hybrid (MAP) combining metal–organic frameworks (MOFs), aggregate‐induced emission luminogens, and Pt nanoparticles is introduced. MAP demonstrates a greater fluorescence quantum yield (62.1%) and greater anti‐photobleaching ability than conventional fluorescent MOFs and organic fluorophores, as well as a 2214‐fold and 16‐fold increase in catalytic capacity over those of horseradish peroxidase and Pt nanoparticles, respectively. The MAP exhibited a slight attenuation after 180 days at room temperature in signal intensity. Polydopamine‐coated polystyrene microsphere‐enabled microchips are economical, user‐friendly, and portable. The combination of MAP and microchips allows for determination using the fluorescence/colorimetric mode in different scenarios. Compared with the enzyme‐linked immunosorbent assay, the fluorescence mode exhibited a 41.9‐fold increase in sensitivity, a 94.2% decrease in time, and an 80.7% decrease in cost. The accuracy of clinical samples reached 100%, and the specificity is 96.2%. Chloramphenicol and enrofloxacin serve as small molecule targets, demonstrating the versatility of this strategy.

中文翻译：

---

基于三元杂交的智能即时微芯片：将 AIEgens 和纳米酶整合到金属有机框架中


疾病风险凸显了即时检测的必要性。在这里，介绍了一种结合了金属-有机框架 （MOF）、聚集诱导发射发光体和 Pt 纳米颗粒的三元杂化 （MAP）。与传统的荧光 MOF 和有机荧光基团相比，MAP 表现出更高的荧光量子产率 （62.1%） 和更强的抗光漂白能力，并且催化能力分别比辣根过氧化物酶和 Pt 纳米颗粒高 2214 倍和 16 倍。MAP 在室温下 180 天后信号强度略有衰减。聚多巴胺包被的聚苯乙烯微球微芯片经济、用户友好且便携。MAP 和微芯片的组合允许在不同情况下使用荧光/比色模式进行测定。与酶联免疫吸附测定相比，荧光模式的灵敏度提高了 41.9 倍，时间缩短了 94.2%，成本降低了 80.7%。临床样本准确率达到 100%，特异度为 96.2%。氯霉素和恩诺沙星作为小分子靶标，证明了该策略的多功能性。